Gilead Sciences (GILD) Tops Q4 EPS by 9c, Offers FY17 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Gild Sciences (GILD) PT Drops to $75 at BMO on Bad Guidance
February 9, 2017 6:41 AM ESTBMO Capital Markets analyst M. Ian Somaiya maintains Market Perform rating, but drops price target on Gild Sciences (NASDAQ: GILD) to $75 (from $88), as the company delivered guidance well below consensus, forcing the Street to cut estimates.
Somaiya comments, "We are maintaining our Market... More
Gilead Sciences (GILD): 'Acquisition Wanted! - Please Apply Within'
February 8, 2017 11:09 AM ESTFollowing its 'kitchen sink' HCV guidance and subsequent 9% sell-off, the urgency for Gilead Sciences (NASDAQ: GILD) to make an acquisition continues to intensify. On the call, the company essentially admitted that it cannot grow over the next few years without a... More
Gilead Sciences (GILD) Pressured on Market Open, Shares Down 10%
February 8, 2017 9:40 AM ESTGilead Sciences (NASDAQ: GILD) Pressured on Market Open, Shares Down 10%
... MoreNeedham & Company Remains Sidelined on Gilead Sciences (GILD) Following 4Q
February 8, 2017 6:57 AM ESTNeedham & Company reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) following the company's 4Q earnings report.
Analyst Alan Carr commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by... More
Gilead (GILD) PT Drops to $87 at Baird on 2017 Guidance
February 8, 2017 6:19 AM ESTBaird analyst Brian Skorney maintains Outperform rating, but lowers price target on Gilead Sciences (NASDAQ: GILD) to $87 (from $100), as the company provided fiscal year revenue guidance well below consensus.
Skorney notes, 2017 guidance likely to bottom out stock. We believe investors were expecting... More
